Skip to main content
. 2018 Jan 5;9(5):6320–6335. doi: 10.18632/oncotarget.23967

Figure 5. Tumor cell viability in human ovarian tumor cell suspensions following treatment with oncolytic adenovirus, recombinant IL-8 or anti-IL-8 antibody.

Figure 5

Cell viability was measured using a MTS assay on days 7-13 after the start of incubation. Viability is presented as percentage of mock group cell viability. Ad = Ad5/3-d24. aIL8=anti-IL-8=anti-IL-8 neutralizing antibody. rIL8=IL-8 = recombinant IL-8. Asterisks indicate the significance of findings: * (p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001). (Panel A) Results from Tumor 1. (Panels B-C) Results from Tumor 2. (Panel D) Results from Tumor 4. (Panels E-F) Results from Tumor 5. (Panels G-H) Results from Tumor 6. (Panel I) Results from Tumor 7.